Sunho Biologics, Inc. (02898) released a monthly return announcement for the period ending 30 November 2025. According to the document, the company’s total authorized share capital remained at US$100,000, composed of 200,000,000 ordinary shares with a par value of US$0.0005 each. No changes occurred during the month.

The report further indicates that the total issued share capital remained unchanged at 156,666,800 ordinary shares, with no treasury shares reported. No share repurchases, conversions, or issuances under options or warrants were disclosed in the filing. The information was provided by Chairman and Executive Director, Zhang Feng, on 2 December 2025.